Preferences help
enabled [disable] Abstract
Number of results
2000 | 47 | 4 | 1147-1157
Article title

Ligands of peroxisome proliferator-activated receptor-γ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages.

Title variants
Languages of publication
Peroxisome proliferator-activated receptors-γ (PPARγ) are ligand-inducible transcription factors of the nuclear hormone receptor superfamily. We examined the effect of PPARγ activation on the generation of vascular endothelial growth factor (VEGF), one of the major angiogenic agents. Rat vascular smooth muscle cells (VSMC) and murine macrophages RAW264.7 were incubated for 24 h with PPARγ activators: prostaglandin J2 and ciglitazone. PPARγ were expressed in VSMC and RAW cells and their activity was upregulated in the presence of PGJ2 and ciglitazone. Incubation of the cells with PPARγ activators significantly augmented the release of VEGF protein into the media, both in resting and in IL-1β- or LPS-stimulated cultures. The higher protein generation was connected with the increased expression of mRNA and transcriptional activation of VEGF promoter. We conclude that the activation of PPARγ upregulates the generation of VEGF and may be involved in the regulation of angiogenesis.
Physical description
  • Department of Clinical Biochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland
  • Department of Cardiology, Innsbruck University, Insbruck, Austria
  • Department of Clinical Biochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland
  • Department of Medical Biochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland
  • Department of Clinical Biochemistry, Collegium Medicum, Jagiellonian University, Krakow, Poland
  • 1. Michalik, L. & Wahli, W. (1999) Peroxisome proliferator-activated receptors: Three isotypes for a multitude of functions. Curr. Opin. Biotechnol. 10, 564-570.
  • 2. Motojima, K., Passilly, P., Peters, J.M. & Gonzales, F.J. (1998) Expression of putative fatty acid transporter genes are regulated by peroxisome proliferator-activated receptor alpha and gamma activators in a tissue- and inducer-specific manner. J. Biol. Chem. 273, 16710-16714.
  • 3. Tontonoz, P., Hu, E., Devine, J., Beale, E.G. & Spiegelman, B.M. (1995) PPARγ2 regulates adipose expression of phosphoenolopyruvate carboxykinase gene. Mol. Cell Biol. 15, 351- 357.
  • 4. Schoonjans, K., Watanabe, M., Suzuki, H., Mahfoudi, A., Krey, G., Wahli, W., Grimaldi, P., Staels, B., Yamamoto, T. & Auwerx, J. (1995) Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter. J. Biol. Chem. 270, 19269-19276.
  • 5. Rodriquez, J.C., Gil-Gomez, G., Hegardt, F.G. & Haro, D. (1994) Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. J. Biol. Chem. 269, 18767-18772.
  • 6. Ribon, V., Johnson, J.H., Camp, H.S. & Saltiel, A.R. (1998) Thiazolidinediones and insulin resistance: Peroxisome proliferator-activated receptor gamma activation stimulates the expression of CAP gene. Proc. Natl. Acad. Sci. U.S.A. 95, 14751-14756.
  • 7. Elstner, E., Muller, C., Koshizuka, K., Wiliamson, E.A., Park, D., Asou, H., Shintaku, P., Said, J.W., Heber, D. & Koeffler, H.P. (1998) Ligands for peroxisome proliferator- activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U.S.A. 95, 8806-8811.
  • 8. Kubota, T., Koshizuka, K., Williamson, E.A., Asou, H., Said, J.W., Holden, S., Miyoshi, I. & Foeffler, H.P. (1998) Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 58, 3344-3352.
  • 9. Sarraf, P., Mueller, E., Jones, D., King, F.J., De Angelo, D.J., Partridge, J.B., Holden, S.A., Chen, L.B., Singer, S., Fletcher, C. & Spiegelman, B.M. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nature Med. 4, 1046-1052.
  • 10. Yoshimoto, T., Naruse, M., Shizume, H., Naruse, K., Tanabe, A., Tanaka, M., Tago, K., Irie, K., Muraki, T., Demura, H. & Zardi, L. (1999) Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy. Atherosclerosis 145, 333-340.
  • 11. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nature Med. 1, 27-31.
  • 12. Schaper, W. & Buschmann, I. (1999) VEGF and therapeutic opportunities in cardiovascular diseases. Curr. Opin. Biotechnol. 10, 541- 543.
  • 13. Adamis, A.P., Miller, J.W., Bernal, M.T., D'Amico, D.J., Yeo, T.K. & Yeo, K.T. (1994) Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative retinopathy. Am. J. Ophthalmol. 118, 445- 450.
  • 14. Aiello, L.P., Avery, R.L., Arring, P.G., Keyt, B.A., Jampel, H.D., Shah, S.T., Pasquale, L.R., Thieme, H., Iwamoto, M.A., Park, J.E., Nguyen, M.S., Aiello, L.M., Ferrara, N. & King, G.L. (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other disorders. N. Engl. J. Med. 331, 1480-1487.
  • 15. Malecaze, F., Favard, C., Simorre-Pinatel, V., Mathis, A., Chollet, P., Favard, C., Bayard, F. & Plouet, J. (1994) Detection of vascular endothelial growth factor messenger RNA and vascular endothelial growth factor-like activity in proliferative diabetic retinopathy. Arch. Ophthalmol 112, 1476-1482.
  • 16. Pe'er, J., Shweiki, D., Itin, A., Hemo, I., Gnessin, H. & Keshet, E. (1995) Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. 72, 638-645.
  • 17. Aiello, L.P., Pierce, E.A., Foley, E.D., Takagi, H., Chen, H., Riddle, L., Ferrara, N., King, G.L. & Smith, L.E.H. (1995) Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U.S.A. 92, 10457-10461.
  • 18. Robinson, G.S., Pierce, E.A., Rook, S.L., Foley, E., Webb, R. & Smith, L.E.S. (1996) Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc. Natl. Acad. Sci. U.S.A. 93, 4851-4856.
  • 19. Adamis, A.P., Shima, D.T., Tolentino, M.J., Gragoudas, E.S., Ferrara, N., Folkman, J., D'Amore, P.A. & Miller, J.W. (1996) Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization. Arch. Ophthalmol. 114, 66-71.
  • 20. Okamoto, N., Tobe, T., Hackett, S.F., Ozaki, H., Vinores, M., LaRochelle, W., Zack, D.J. & Campochiaro, P.A. (1997) Transgenic mice with increased expression of vascular endothelial growth factor in the retina. A new model of intraretinal and subretinal neovascularization. Am. J. Pathol. 151, 281-291.
  • 21. Xin, X., Suya, Y., Kowalski, J. & Gerristen, M.E. (1999) Peroxisome proliferator-activated receptor-gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J. Biol. Chem. 274, 9116-9121.
  • 22. Bishop-Bailey, D. & Hla, T. (1999) Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy-delta12, 14-prostaglandin J2. J. Biol. Chem. 274, 17042-17048.
  • 23. Chomczynski, P. & Sacchi, N. (1987) Single step method of RNA isolation by acid guanidinum thiocyanate-phenol-chlorophorm extraction. Anal. Biochem. 162, 156-159.
  • 24. Yu, K., Bayona, W., Kallens, C.B., Harding, H.P., Ravera, C.P., McMahon, G., Brown, M., & Lazar, M.A. (1995) Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270, 23975- 23983.
  • 25. Yamakawa, K., Hosoi, M., Koyama, H., Tanaka, S., Fukumoto, S., Morii, H., & Nishizawa, Y. (2000) Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cell. Biochem. Biophys. Res. Commun. 271, 571- 574.
  • 26. Bamba, H., Ota, S., Kato, A., Kawamoto, C., Fujiwara, K. (2000) Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. Biochem. Biophys. Res. Commun. 273, 485-491.
  • 27. Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A., Evans, R.M. (1998) PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93, 241-252.
  • 28. Ricote, M., Huang, J., Fajas, L., Li, A., Welch, J., Najib, J., Witzum, J.L., Auwerx, J., Palinski, W. & Glass, C.K. (1998) Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized LDL. Proc. Natl. Acad. Sci. U.S.A. 95, 7614-7619.
  • 29. Steals, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I.P., Delerive, P., Fadel, A., Chinetti, G., Fruchard, J.C., Najib, J., Maclouf, J. & Tedgui, A. (1998) Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393, 790-793.
  • 30. Iijima, K., Yoshizumi, M., Ako, J., Eto, M., Kim, S., Hashimoto, M., Sugimoto, N., Liang, Y.Q., Sudoh, N., Toba, K. & Ouchi, Y. (1998) Expression of peroxisome proliferator-activated receptor-γ (PPARγ) in rat aortic smooth muscle cells. Biochem. Biophys. Res. Commun. 247, 353-356.
  • 31. Pasceri, V., Wu, H.D., Willerson, J.T. & Yeh, E.T.H. (2000) Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activator. Circulation 101, 235-240.
  • 32. Ricote, M., Li, A.C., Willson, T.M., Kelly, C.J. & Glass, C.K. (1998) The peroxisome proliferator-activated receptor gamma is a negative regulator of macrophage activation. Nature 391, 79-82.
  • 33. Jiang, C., Ting, A.T. & Seed, B. (1998) PPARgamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391, 82-86.
  • 34. Momoi, A., Murao, K., Imachi, H., Yoshitaka, S., Nakamura, H., Hosokawa, H., Sato, M., Fujita, J., Okada, H., Ishida, T. & Takahara, J. (1999) Thiazolidinedione inhibits production of RANTES in cytokine-treated human lung epithelial cell line. FEBS Lett. 452, 301-304.
  • 35. Murao, K., Imachi, H., Atsuko, M., Sayo, Y., Hosokawa, H., Sato, M., Ishida, T. & Takahara, J. (1999) Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett. 454, 27-30.
  • 36. Law, R.E., Meehan, W.P., Xi, X.P., Graf, K., Wuthrich, D.A., Coats, W., Faxon, D. & Hsueh, W.A. (1996) Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J. Clin. Invest. 98, 1897-1905.
  • 37. Kihara, S., Ouchi, N., Funahashi, T., Shinohara, E., Tamura, R., Yamashita, S. & Matsuzawa, Y. (1998) Troglitazone enhances glucose uptake and inhibits mitogen-activated protein kinase in human aortic smooth muscle cells. Atherosclerosis 136, 163-168.
  • 38. Papapetropoulos, A., Garcia-Cardena, G., Madri, J.A. & Sessa, W.C. (1997) Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100, 3131-3139.
  • 39. Parenti, A., Mordibelli, L., Cui, X.L., Douglas, J.G., Hood, J.D., Granger, H.J., Ledda, F. & Ziche, M. (1998) Nitric oxide is a upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase-1/ 2 activation in postcapillary endothelium. J. Biol. Chem. 273, 4220-4226.
  • 40. Satoh, H., Tsukamoto, K., Hashimoto, Y., Hashimoto, N., Togo, M., Hara, M., Maekawa, H., Isoo, N., Kimura, S. & Watanabe, T. (1999) Thiazolidinediones suppress endothelin-1 secretion from bovine endothelial cells: A new possible role of PPARγ on vascular endothelial function. Biochem. Biophys. Res. Commun. 254, 757-763.
  • 41. Delerive, P., Martin-Nizard, F., Chinetti, G., Trottein, F., Fruchard, J.C., Najib, J., Duriez, P. & Steals, B. (1999) Peroxisome proliferator- activated receptor activators inhibit thrombin- induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ. Res. 85, 394-402.
  • 42. Aiello, L.P. (1997) Vascular endothelial growth factor and the eye: Biochemical mechanisms of action and implications for novel therapies. Ophthalmic Res. 29, 354-362.
  • 43. Hammes, H.P., Lin, J., Bretzel, R.G., Brownle, M. & Breier, G. (1998) Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 47, 401-406.
  • 44. Kimura, H., Weisz, A., Karashima, Y., Hashimoto, K., Ogura, T., D'Acqusto, F., Addeo, R., Makuchi, M. & Esumi, H. (2000) Hypoxia reponse element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: Control of hypoxia inducible factor-1 activity by nitric oxide. Blood 95, 189-197.
  • 45. Finkenzeller, G., Sparacio, A., Technau, A., Marme, D. & Siemeister, G. (1997) SP1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet derived growth factor-induced gene expression. Oncogene 15, 669-676.
  • 46. Ryuto, M., Ono, M., Izumi, H., Yoshida, S., Weich, H.A., Kohna, K. & Kuwano, M. (1996) Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Possible roles of SP-1. J. Biol. Chem. 271, 28220-28228.
  • 47. Krey, G., Mahfoudi, A. & Wahli, W. (1995) Functional interactions of peroxisome proliferator-activated receptor, retinoid X-receptor, and SP1 in the transcriptional regulation of the acyl-coenzyme A oxidase promoter. Mol. Endocrinol. 9, 219-31.
  • 48. Missbach, M., Jagher, B., Siga, I., Nayeri, S., Carlberg, C. & Wiesenberg, I. (1996) Thiazolidine diones specific ligands of the nuclear receptor retinoid Z receptor/retinoid acid receptor-related orphan receptor alpha with potent antiarthritic activity. J. Biol. Chem. 271, 13515-13522.
  • 49. Winrow, C.J., Capone, J.P. & Rachubinski, R.A. (1998) Cross-talk between orphan nuclear hormone receptor RZRalpha and peroxisome activated-receptor α in regulation of the peroxisome hydratase-dehydrogenase gene. J. Biol. Chem. 273, 31442-31448.
  • 50. Kitamura, Y., Kakimura, J., Matsuoka, Y., Nomura, Y., Gebicke-Haerter, P.J. & Taniguchi, T. (1999) Activators of peroxisome proliferator-activated receptor-γ (PPARγ) inhibit inducible nitric oxide synthase expression but increase heme oxygenase-1 expression in rat glial cells. Neurosci. Lett. 262, 129-132.
  • 51. Jozkowicz, A., Placha, W., Krzesz, R., Dulak, J. & Dembinska-Kiec, A. (2000) Effect of linoleic acid on the expression of nitric oxide synthase and heme oxygenase-1 in rat vascular smooth muscle cells;in Advances in Lipoprotein and Atherosclerosis Research. Proc. 10th International Dresden Symposium on Lipoprotein and Atherosclerosis, in press.
  • 52. Dulak, J., Jozkowicz, A., Foresti, R., Green, C. & Motterlini, R. (1999) Regulation of VEGF synthesis in vascular smooth muscle cells by carbon monoxide and nitric oxide metabolic pathways. Angiogenesis and Tumors, pp. 22-25, October 1999, Paris, France. Abstract.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.